Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25188474 | 1.00 | CRBN (0.39) | CRBNDDB1HPGDSGSPT1CYP11B1 | |
| SCHEMBL25201161 | 1.00 | CRBN (0.39) | CRBNDDB1HPGDSGSPT1CYP11B1 | |
| SCHEMBL30441557 | 0.94 | CRBN (0.38) | CRBNDDB1HPGDSGSPT1CYP11B1 | |
| SCHEMBL25195054 | 0.94 | CRBN (0.38) | CRBNDDB1HPGDSGSPT1CYP11B1 | |
| SCHEMBL25501837 | 0.94 | CRBN (0.38) | CRBNDDB1HPGDSGSPT1CYP11B1 | |
| SCHEMBL25190776 | 0.92 | CRBN (0.43) | CRBNDDB1GSPT1 | |
| SCHEMBL30442535 | 0.92 | CRBN (0.43) | CRBNDDB1GSPT1 | |
| SCHEMBL25190774 | 0.92 | CRBN (0.43) | CRBNDDB1GSPT1 | |
| SCHEMBL25502446 | 0.87 | DDB1 (0.48) | CRBNDDB1 | |
| SCHEMBL25199468 | 0.86 | CRBN (0.44) | CRBNDDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4430052-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | TTK, HIPK1, CLK1 | CRBN 218/4885DDB1 675/4885HPGDS 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.